Efficacy and safety of temperature-controlled intraductal radiofrequency ablation in advanced malignant hilar biliary obstruction: A pilot multicenter randomized comparative trial
- Authors
- Kang, Huapyong; Han, Sung Yong; Cho, Jae Hee; Kim, Eui Joo; Kim, Dong Uk; Yang, Jae Kook; Jeon, Soyoung; Park, Goeun; Lee, Tae Hoon
- Issue Date
- Apr-2022
- Publisher
- Springer Verlag
- Keywords
- cholangiocarcinoma; cholangiopancreatography; cholestasis; endoscopic retrograde; gallbladder neoplasms; radiofrequency ablation
- Citation
- Journal of Hepato-Biliary-Pancreatic Sciences, v.29, no.4, pp 469 - 478
- Pages
- 10
- Journal Title
- Journal of Hepato-Biliary-Pancreatic Sciences
- Volume
- 29
- Number
- 4
- Start Page
- 469
- End Page
- 478
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20732
- DOI
- 10.1002/jhbp.1082
- ISSN
- 1868-6974
1868-6982
- Abstract
- Purpose We aimed to evaluate the efficacy and safety of temperature-controlled intraductal radiofrequency ablation (ID-RFA) for advanced malignant hilar biliary obstruction (MHBO). Methods Patients were randomly assigned to RFA group (ID-RFA and bilateral plastic stent [PS]) or non-RFA group (bilateral PS) at a 1:1 ratio. Exchange to self-expanding metal stent (SEMS) was performed after 3 months or when premature PS occlusion occurred. Total event-free stent patency, overall survival (OS), and adverse events (AEs) were analyzed. Results A total of 30 patients from three hospitals were enrolled. Stent patency and OS did not differ between the two groups (178 days vs 122 days, P = .154; 230 days vs 144 days, P = .643; respectively). In patients with each stricture length >= 11 mm on both sides, stent patency was longer in the RFA group than in the non-RFA group (175 days vs 121 days, P = .028). More patients received elective exchange to SEMS without PS occlusion in the RFA group than in the non-RFA group (69.2% vs 23.1%, P = .018). AE rates did not differ between the two groups. Conclusions Temperature-controlled ID-RFA for advanced MHBO was safe and feasible. It could prevent premature PS occlusion within 3 months.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20732)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.